Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBNP for acute decompensated heart failure (cardiac, inflammatory and mitochondrial effects)
ChiCTR2500114718Phase 4Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of nesiritide in heart failure (HF) (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Change in NT-proBNP level at 72 hours. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
nesiritide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2500114718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114718.